Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Lymphoid 1

Conditions

Hemophilia A 2Lymphoma, Follicular 1

Interventions

Cyclophosphamide 3167Cisplatin 3163Carboplatin 2940Paclitaxel 2675Radiotherapy 2648Gemcitabine 2548pembrolizumab 2334Docetaxel 2158Bevacizumab 2129Fluorouracil 1822Capecitabine 1785Oxaliplatin 1713Dexamethasone 1591Nivolumab 1517Doxorubicin 1479Rituximab 1455Etoposide 1342Magnetic Resonance Spectroscopy 1270Irinotecan 1235Leucovorin 1217Cytarabine 1124Pemetrexed 1064Drug Therapy 1062fludarabine 1052Vincristine 958Specimen Handling 940Prednisone 927Cetuximab 921Lenalidomide 917Trastuzumab 903

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Factor VIII × Clear all
NCT02847637 2022-11-16

HAVEN 3

Hoffmann-La Roche

Phase 3 Completed
152 enrolled 46 charts 1 FDA
Classical hematology

Hemophilia A

NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡